Fidaxomicin for Clostridium difficile (Dificlir)
Comprehensive guide to Fidaxomicin (Dificlir) for treating Clostridium difficile infection, including dosage, side effects, and comparisons with vancomycin.
Fidaxomicin, sold under the brand name Dificlir, is a specialized oral antibiotic designed to treat Clostridium difficile (now Clostridioides difficile or C. difficile) infection, a major cause of antibiotic-associated diarrhea.
This infection leads to symptoms ranging from mild diarrhea to severe colitis and can be life-threatening, particularly in hospitalized patients or those with recent antibiotic exposure. Fidaxomicin stands out for its narrow-spectrum activity, which targets C. difficile effectively while sparing beneficial gut bacteria, resulting in lower recurrence rates compared to standard treatments like vancomycin.
About fidaxomicin tablets
Fidaxomicin is a first-in-class macrocyclic lactone antibiotic with bactericidal action against C. difficile. It works by inhibiting bacterial RNA polymerase, preventing transcription and bacterial replication. Unlike bacteriostatic agents like vancomycin, fidaxomicin is bactericidal, exhibits lower minimum inhibitory concentrations (MICs), and has a prolonged post-antibiotic effect of about 10 hours, supporting twice-daily dosing.
Key advantages include suppression of toxin production and sporulation at subinhibitory concentrations, which vancomycin and metronidazole fail to achieve. This reduces spore shedding, lowers recurrence risk, and minimizes environmental transmission. Clinical trials (OPT-80-003 and OPT-80-004) showed fidaxomicin (200 mg twice daily for 10 days) was noninferior to vancomycin (125 mg four times daily) for clinical cure (~87% in both arms) but superior for sustained response and recurrence prevention (relative reduction of 39-53%).
In high-risk groups—such as those over 65, with renal impairment, cancer, or concomitant antibiotics—fidaxomicin reduced recurrence by up to 60% and improved sustained response by 85%. For immunocompromised patients, it significantly lowers poor outcomes compared to vancomycin.
Before taking fidaxomicin tablets
Allergy
Do not take fidaxomicin if you are allergic to it or any ingredients. Rare hypersensitivity reactions, including anaphylaxis, have been reported. Inform your doctor of any allergies.
Pregnancy and breastfeeding
Limited data exist on fidaxomicin use in pregnancy; it is minimally absorbed systemically (<1%), suggesting low fetal risk, but consult your doctor. For breastfeeding, trace amounts may appear in milk; weigh benefits against risks.
Babies and children
Approved for pediatric patients aged 6 months and older with C. difficile-associated diarrhea. Dosing is weight-based. Use in younger children requires specialist advice.
Adults aged 65 or over
Safe and particularly beneficial in older adults, who face higher recurrence risks. Subgroup analyses confirm 60% lower recurrence vs. vancomycin after adjustments for age and comorbidities.
Other medicines, foods, and drink
- No significant food interactions; can be taken with or without meals.
- Avoid concomitant use with strong CYP3A4 inducers (e.g., rifampin), as they may reduce efficacy.
- No major interactions with common antibiotics, but inform your doctor of all medications.
Having an operation or dental treatment
Tell your doctor or dentist about fidaxomicin, though systemic absorption is negligible, minimizing interaction risks.
Taking other antibiotics
Fidaxomicin excels in patients on concomitant antibiotics, achieving 90% clinical cure vs. 79% with vancomycin and lower recurrence (17% vs. 29%).
How and when to take fidaxomicin
Dosage
Standard adult dose: 200 mg orally twice daily for 10 days. Pediatric dosing (≥6 months): 130 mg twice daily if 9-<18 kg; higher for heavier children.
| Patient Group | Dose | Frequency | Duration |
|---|---|---|---|
| Adults | 200 mg | Twice daily | 10 days |
| Children 9-<18 kg | 130 mg | Twice daily | 10 days |
| Children ≥18 kg | 200 mg | Twice daily | 10 days |
How to take it
Swallow tablets whole with water. If you miss a dose, take it as soon as remembered unless near the next dose; do not double up.
If you forget to take fidaxomicin tablets
Take the missed dose promptly if within a few hours; skip if almost time for the next. Consistency is key for efficacy against spores. Contact your doctor if multiple doses are missed.
If you take too much fidaxomicin
Overdose is unlikely due to poor absorption. Seek medical help if concerned; symptoms are rare but may include nausea.
Side-effects of fidaxomicin tablets
Fidaxomicin has a favorable safety profile with minimal systemic effects due to <1% absorption. Common side effects (>1/100):
- Vomiting (9-13%)
- Nausea (5-8%)
- Abdominal pain (5-6%)
- Gastrointestinal hemorrhage (rare, 2-4% in trials)
Serious effects (rare): C. difficile overgrowth (monitor symptoms), allergic reactions. Asymptomatic leukocytosis may occur but resolves. Report persistent diarrhea or blood in stool immediately.
How to cope with side effects of fidaxomicin
- Nausea/vomiting: Take with food; small, frequent meals. Ginger tea or antiemetics if needed.
- Abdominal pain: Rest, heat pad; avoid irritants like caffeine.
- Stay hydrated; probiotics may support flora recovery post-treatment.
Pregnancy and breastfeeding while taking fidaxomicin tablets
Category B (animal studies show no risk); human data limited. Negligible systemic exposure suggests safety, but use only if clearly needed. Pump and discard milk if concerned during treatment.
Common questions about fidaxomicin tablets
How long does it take to work?
Resolution of diarrhea typically within 2-5 days; full course required to prevent recurrence.
Is fidaxomicin better than vancomycin?
Equivalent clinical cure but superior sustained response (lower recurrence by ~40%) due to microbiome preservation and anti-sporulation effects.
Can it be used for recurrent CDI?
Yes, effective for initial and recurrent episodes, especially in high-risk patients.
Does it affect gut bacteria?
Minimal disruption; fecal anaerobe reduction is less than with vancomycin, aiding recolonization.
Analyses of clinical studies
Two pivotal Phase 3 trials (n=1,057) confirmed noninferiority for cure and superiority for global cure. Fidaxomicin reduced spores by 2.3 log10 CFU/g vs. vancomycin at day 28. In non-NAP1/027 strains, benefits were pronounced. Cost-effectiveness varies by recurrence risk and willingness-to-pay thresholds.
Further reading and references
For more on C. difficile management, refer to IDSA guidelines. Fidaxomicin is recommended as first-line for non-severe initial/recurrent CDI in high-risk patients.
Date reviewed: 2025
This article reflects evidence up to 2025, prioritizing recent trials.
Frequently Asked Questions (FAQs)
Q: What is fidaxomicin used for?
A: Primarily for Clostridioides difficile-associated diarrhea in adults and children ≥6 months.
Q: How does fidaxomicin compare to vancomycin?
A: Similar cure rates but 40% lower recurrence; preserves gut flora better.
Q: What are the main side effects?
A: Nausea, vomiting, abdominal pain; generally mild.
Q: Can children take it?
A: Yes, from 6 months with weight-based dosing.
Q: Is it safe in pregnancy?
A: Limited data; low absorption suggests low risk—consult physician.
References
- Fidaxomicin in Clostridium difficile infection: latest evidence and clinical implications — Johnson S et al. PMC. 2014-02-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3926343/
- Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection — Crook DW et al. PMC. 2015-12-31. https://pmc.ncbi.nlm.nih.gov/articles/PMC4692299/
- Fidaxomicin (Dificid) for Clostridium difficile Infection — American Academy of Family Physicians. 2013-02-01. https://www.aafp.org/pubs/afp/issues/2013/0201/p211.html
- Fidaxomicin: Uses, Interactions, Mechanism of Action — DrugBank Online. 2025 (updated). https://go.drugbank.com/drugs/DB08874
- Comparative Effectiveness of Fidaxomicin vs Vancomycin in Immunocompromised Patients — Oxford University Press. 2024-01-01. https://academic.oup.com/ofid/article/11/1/ofad622/7462571
- Fidaxomicin: MedlinePlus Drug Information — U.S. National Library of Medicine. 2025 (updated). https://medlineplus.gov/druginfo/meds/a611040.html
Similar Articles
Read full bio of medha deb
